Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer

Abstract

ClinicalTrials.gov Identifier: NCT00551369.

Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy

“…Extent of resection included lobectomy (94%), bilobectomy (4%), and wedge resection (2%). The median number of N1 nodes sampled was 5 (range: [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], and the median number of N2 nodes sampled was 5 (range: 1-27).…”

“…7,10-13 As investigations of SBRT are performed in high-risk and operable patients, the significance of occult nodal disease may be greater and further investigation of appropriate staging techniques is critical. 14,15 Currently, limited data exist on the role of PET/CT in specifically identifying isolated N1 disease for patients with clinically staged I NSCLC who would be considered for SBRT.…”

A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial)

“…The 3-year overall survival (OS) was 59.9% in 100 inoperable patients and no severe toxicities were observed (3). Based on the results of JCOG0403 and several Phase II studies from Western countries showing that SBRT is effective and safe (4)(5)(6), guidelines from the National Comprehensive Cancer Network (NCCN) and The Japan Lung Cancer Society recommend that SBRT can be considered a standard treatment choice for patients with Stage I NSCLC who are inoperable or refuse operation (2,7).…”

Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence

“…In the preliminary results of the Radiation Therapy Oncology Group (RTOG) 0618 phase II trial including 26 evaluable patients, the total prescribed SABR dose was 54 Gy delivered in 3 fractions. The 2-year estimates of local failure (primary tumor plus involved lobe failure), regional failure, and distant failures rates were 19.2%, 11.7%, and 15.4%, respectively (21).…”